Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer’s disease

This report presents a neuropathological analysis of six Alzheimer’s disease patients treated with aducanumab.

Aducanumab was the first disease-modifying monoclonal antibody approved for Alzheimer’s disease.

No numerical data or trial data provided in the source material.

Neuropathological changes in aducanumab-treated patients were assessed in comparison to untreated Alzheimer’s disease patients.
Six additional aducanumab clinical trial participants consented to autopsy, providing new insights into treatment effects.
Only eight autopsy cases of aducanumab-treated individuals have been reported to date.
Neuropathological assessments can link biomarker trajectories to cellular and molecular changes in the brain.
Understanding the brain's response post-treatment discontinuation is critical for future therapeutic strategies.

Continued research is necessary to understand the effects of such treatments on brain pathology.

This neuropathological investigation enhances the understanding of aducanumab's impact on Alzheimer’s disease.

Clinical Report: Investigation of Neuropathological Changes Induced by Aducanumab